TABLE 1 .
Phenotypic resistance of CC80 isolatesa
| Clade and organism (n) | No. (%) of isolates |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitive | Resistant to: |
|||||||||
| Cef | Ery | Clin | Fus | Tet | Kan | Mup | Nor | Rif | ||
| Basal | ||||||||||
| MSSA (13) | 6 (46) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 7 (54) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Derived | ||||||||||
| MSSA (10) | 0 (0) | 0 (0) | 2 (20) | 1 (10) | 6 (60) | 5 (50) | 1 (10) | 0 (0) | 0 (0) | 1 (10) |
| MRSA (74) | 0 (0) | 74 (100) | 15 (20) | 14 (19) | 65 (88) | 57 (77) | 68 (92) | 1 (1) | 4 (5) | 0 (0) |
| Total (97) | 6 (6) | 74 (76) | 17 (18) | 15 (15) | 71 (73) | 69 (71) | 69 (71) | 1 (1) | 4 (4) | 1 (1) |
a
Antimicrobial-resistant CC80 isolates from the basal and derived clades in relation to mecA status. Cef, cefoxitin; Ery, erythromycin; Clin, clindamycin; Fus, fusidic acid; Tet, tetracycline; Kan, kanamycin; Mup, mupirocin; Nor, norfloxacin; Rif, rifampin.